Retatrutide

Overview

Adds glucagon-receptor agonism to the incretin pair, which raises energy expenditure on top of appetite suppression. Phase 2 weight-loss results are the largest yet reported for a pharmacological agent, but long-term safety is genuinely unknown.

How it works

Simultaneous agonism at three receptors. GLP-1 and GIP reduce intake and improve insulin dynamics; glucagon-receptor activation increases hepatic fat oxidation and resting energy expenditure — the same axis that makes glucagon a stress hormone, which is why cardiac and glycemic effects need close scrutiny.

Evidence base

Rated 3 of 5 — Moderate. Small or early-phase human trials, or good controlled topical human data.

• Phase 2 only, in the public domain. Phase 3 results pending.
• Peer-reviewed publication exists for phase 2 obesity data.

Benefits & potential uses

Bars indicate how well each claim is supported: three = strong human evidence, two = moderate, one = preliminary or preclinical.

• Largest reported pharmacologic weight loss Moderate evidence

  Phase 2 data showed roughly 24% mean body-weight reduction at 48 weeks on the highest dose, with weight curves that had not yet plateaued.

• Marked hepatic fat reduction Moderate evidence

  A sub-study reported near-complete normalization of liver fat content in most participants with steatosis.

• Increased energy expenditure Preliminary

  The glucagon component adds a thermogenic mechanism absent from GLP-1-only drugs, in principle limiting metabolic adaptation.

Risks, cons & cautions

Bars indicate seriousness: three = serious or common, two = moderate, one = minor.

• No phase 3 safety data yet Serious

  Every claim about long-term safety is extrapolation. Approval is not guaranteed and prior obesity drugs have failed at exactly this stage.

• Dose-dependent heart-rate increase Serious

  Phase 2 showed increases in heart rate that peaked mid-trial. Cardiovascular outcome data do not yet exist.

• Glucose elevation potential Moderate evidence

  Glucagon agonism can raise hepatic glucose output; net glycemic effect depends on the balance with incretin activity.

• Severe GI effects at high doses Moderate evidence

  Nausea and vomiting were the dominant adverse events and drove discontinuations.

• Entirely unregulated supply Serious

  All retatrutide sold to consumers is illicit. There is no verified identity, purity, sterility, or dose accuracy, and no recourse if harmed.

Who should avoid it

• Everyone outside a registered clinical trial — there is no lawful or quality-assured route to this compound

If used under medical supervision, monitor

• Not applicable outside trial settings

Commonly confused with

These mix-ups cause real harm — two products sold under one name, or two molecules whose effects run in opposite directions.

Regulatory & legal status

Investigational. Not approved by FDA, EMA, or any comparable regulator. Sale for human use is unlawful; "research chemical" labelling does not change that.

Infographic

Retatrutide — benefits & risks at a glance Download SVG

Where to read further

We link to live literature searches rather than a frozen citation list, so you always see current results — including anything published after our last review.

• PubMed — all published literature on Retatrutide
• PubMed — randomized controlled trials only
• ClinicalTrials.gov — registered human trials

Related peptides in Metabolic & Weight